Skip to main content
Clinical Trials/2025-521559-22-00
2025-521559-22-00
Not yet recruiting
Phase 2/3

Pre- and post-treatment evaluation of lung function with Xenon-gas enhanced Dual-Energy CT-imaging in patients undergoing radiotherapy

UZ Brussel1 site in 1 country40 target enrollmentStarted: October 22, 2025Last updated:

Overview

Phase
Phase 2/3
Status
Not yet recruiting
Sponsor
UZ Brussel
Enrollment
40
Locations
1
Primary Endpoint
The primary endpoint of this study is to quantify radiotherapy-induced functional and anatomical changes by comparing pre- and post-treatment ventilation maps. Radiotherapy-induced changes will be assessed both qualitatively, by visual analysis of differences in lung parenchyma structure and ventilation patterns (hypo- or hyperdense areas on colour coded Xe-concentration maps of the lungs), and quantitatively, by computing local differences in ventilation metrics between pre- and post-treatment.

Overview

Brief Summary

The primary objective of this trial is to acquire high-resolution anatomical and functional information on lung ventilation using a gas mixture of 30 Vol% Xe in 70 Vol% O2 as contrast agent in combination with DECT-imaging in lung and breast cancer patients scheduled to undergo radiotherapy. Ventilation maps will be generated to evaluate the effect of radiotherapy on the lung parenchyma in lung and breast cancer patients.

Eligibility Criteria

Ages
18 years to 65+ years (65+ Years, 18-64 Years)
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Lung and breast cancer having a TNM classification I-IIIa.
  • Between 50 and 80 years old.
  • No prior cancer treatment.
  • Breath hold for 3 seconds
  • Patients who are in stable condition or who are not hospitalized in an ICU.
  • Patients who are not suffering from COPD GOLD IV.
  • Patients who signed informed consent forms.

Exclusion Criteria

  • No lung or breast cancer having a TNM classification I-IIIa.
  • Younger than 50 or older than 80 years old.
  • Received prior cancer treatment.
  • Cannot perform a 3 s breath hold
  • Patients who are in an unstable condition or who are hospitalized in ICU.
  • Patients who are suffering from COPD GOLD IV.
  • Patients who did not sign informed consent forms.

Outcomes

Primary Outcomes

The primary endpoint of this study is to quantify radiotherapy-induced functional and anatomical changes by comparing pre- and post-treatment ventilation maps. Radiotherapy-induced changes will be assessed both qualitatively, by visual analysis of differences in lung parenchyma structure and ventilation patterns (hypo- or hyperdense areas on colour coded Xe-concentration maps of the lungs), and quantitatively, by computing local differences in ventilation metrics between pre- and post-treatment.

The primary endpoint of this study is to quantify radiotherapy-induced functional and anatomical changes by comparing pre- and post-treatment ventilation maps. Radiotherapy-induced changes will be assessed both qualitatively, by visual analysis of differences in lung parenchyma structure and ventilation patterns (hypo- or hyperdense areas on colour coded Xe-concentration maps of the lungs), and quantitatively, by computing local differences in ventilation metrics between pre- and post-treatment.

Secondary Outcomes

  • The secondary endpoint of this trial is to perform an extensive evaluation on the effect of RT on the lung parenchyma of lung- and breast cancer patients using ventilation metrics derived using a gas mixture of 30Vol% Xe in 70Vol% O2 as contrast agent combined with DECT.

Investigators

Sponsor
UZ Brussel
Sponsor Class
Hospital/Clinic/Other health care facility
Responsible Party
Principal Investigator
Principal Investigator

Nico Buls

Scientific

UZ Brussel

Study Sites (1)

Loading locations...

Similar Trials